Skip to content

Clinical trial for safety, effectiveness, and economic evaluation of Ukgansangajinpibanha in subjects with autism spectrum disorder

Safety, effectiveness, and economic evaluation of a herbal medicine, Ukgansangajinpibanha granule, in subjects with autism spectrum disorder: a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group, clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003007
Enrollment
120
Registered
2018-07-20
Start date
2018-08-20
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Procedure/Surgery : 1. Ukgansangajinpibanha granule 1.5 g, twice/day, total 84 days, per os 2. GV20 (Backhoe), GV24 (Sinjeong), EX-HN1 (Sasinchong) Acupuncture, twice/week, total 24 times, 10-15

Sponsors

Kyung Hee University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Children from 4-year-old to 6-year-old 2) Children who have received an autism spectrum disorder-specific medical certificate from the doctor (e.g. autistic disorder, Asperger’s syndrome, or pervasive developmental disorder-not otherwise specified) 3) CARS (Childhood Autism Rating Scale) score = 30 in the screening test 4) Agreement of written informed consent by sign of representative

Exclusion criteria

Exclusion criteria: 1) Hereditary syndromes including Rett syndrome, Down syndrome, or fragile X syndome 2) Other mental disorders including selective mutism, attention deficit hyperactivity disorder, schizophrenia, or depressive disorder 3) Hereditary metabolic diseases including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 4) Recently operated children, seizures including epilepsy, generalized infections needed antibiotics, brain injuries including cerebral palsy, or severe chronic or terminal illness including malignancy or tuberculosis 5) Children who have taken risperidone or aripiprazole, or less than 3 months after withdrawal 6) Children who took Korean medicine in past 1 month 7) AST, ALT, BUN, or Creatinine > three times of the normal upper limit 8) Hypersensitivity to test drug or placebo 9) Difficulty in swallowing test drug or placebo 10) Intolerance or fear of acupuncture 11) Hemostatic disorders 12) Participated another clinical trial within 1 month 13) Inappropriate to participate in the trial determined by trial director or personnel

Design outcomes

Primary

MeasureTime frame
Childhood Autism Rating Scale (CARS)

Secondary

MeasureTime frame
Aberrant Behavior Checklist (ABC (2));Autism Behavior Checklist (ABC);Social Maturity Scale (SMS);Child Health Questionnaire-Parent Form 28 (CHQ-PF28);EuroQoL Five-Dimension Five-Level Youth Proxy 1 (EQ-5D-Y Proxy 1);Adverse reaction;Korean Parenting Stress Index-Short Form (K-PSI-SF)

Countries

Korea, Republic of

Contacts

Public ContactSun Haeng Lee

Kyung Hee University Oriental Medical Center

civil011@empas.com+82-2-958-1719

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 21, 2026